ILMN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Illumina Inc (ILMN) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has some positive analyst sentiment and bullish moving averages, the lack of significant positive catalysts, insider selling, and the technical indicators showing a neutral to bearish trend suggest that it is better to hold off on investing right now.
The MACD is negatively expanding (-1.01), indicating bearish momentum. RSI is neutral at 50.544, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 162.133, with resistance at 167.127 and support at 157.138. However, candlestick pattern analysis suggests a potential decline of -4% in the next week and -6.56% in the next month.
Analysts have recently upgraded the stock, with Guggenheim raising the price target to $180 and RBC Capital resuming coverage with an Outperform rating. The company is seen as having strong clinical momentum and fading competitive risks.
Insiders are selling heavily, with a 17343.19% increase in selling activity over the last month. There is no recent news or event-driven catalysts to support a bullish case. Additionally, the stock trend analysis suggests potential short-term declines.
No financial data available for the latest quarter.
Analysts are mixed but leaning positive. Recent upgrades and price target increases from Guggenheim ($180), RBC Capital ($170), and Daiwa ($155) reflect optimism about the company's clinical sequencing market hold and growth potential. However, some analysts, like Citi and Canaccord, remain cautious due to competitive risks and reduced revenue projections.
